Study on extracellular matrix metalloproteinase inducer and human epidermal growth factor receptor-2 protein expression in papillary thyroid carcinoma using a quantum dot-based immunofluorescence technique

The aim of the present study was to investigate the association of extracellular matrix metalloproteinase inducer (EMMPRIN) and human epidermal growth factor receptor (HER)-2 protein expression in papillary thyroid carcinoma with lymph node metastasis (LNM), as well as the correlation between the two types of protein expression. A quantum dot-based immunofluorescence technique was used to detect EMMPRIN and HER-2 protein expression in 75 papillary thyroid carcinoma cases (including 70 cases of papillary thyroid carcinoma tissues and 5 cases of peri-tumor tissues). The positive rate and expression of EMMPRIN and HER-2 were compared and observed. The positive rate of EMMPRIN was 75.71% in papillary thyroid carcinoma tissues and 20.00% in peri-tumor tissues (P<0.05). The positive rate of HER-2 was 45.71% in papillary thyroid carcinoma tissues and 0% in peri-tumor tissues (P>0.05). The expression of EMMPRIN and HER-2 in papillary thyroid carcinoma was significantly associated with LNM (P<0.05). In addition, in the 70 papillary thyroid carcinoma tissues, the expression of EMMPRIN and HER-2 was positively and significantly correlated. In conclusion, this study demonstrates that the co-evolution of EMMPRIN and HER-2 may promote the occurrence and development of papillary thyroid carcinoma and LNM.

The inflammatory breast: management, decision-making algorithms, therapeutic principles

Inflammatory syndrome is one of the rare emergency breast situations. Its etiology is benign, infectious in most cases. The clinical examination is often self-evident and suggests the diagnosis. But alone it is insufficient, and diagnostic tests are necessary to guide therapy. As essential as it is, mammography's limitations reinforce the benefit of ultrasonography, which in all cases reveals an abscess and has greater sensitivity for detecting a malignant tumor. If the etiology is benign, clinical signs will disappear with medical treatment, with no need for further investigation. While it is legitimate to initiate a trial treatment, it must not delay oncologic management, because of the severity of inflammatory cancer.